UBS AM
SGMO

UBS AM’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

UBS AM’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-152,662
Closed -$269K – 2673
2023
Q2 		$269K Hold
152,662
– – ﹤0.01% 2503
2023
Q1 		$269K Buy
152,662
+19,108
+14% +$54.5K ﹤0.01% 2503
2022
Q4 		$419K Hold
133,554
– – ﹤0.01% 2242
2022
Q3 		$654K Sell
133,554
-7,272
-5% -$37.4K ﹤0.01% 2210
2022
Q2 		$583K Buy
140,826
+15,538
+12% +$67.2K ﹤0.01% 2246
2022
Q1 		$728K Buy
125,288
+5,638
+5% +$33.5K ﹤0.01% 2294
2021
Q4 		$897K Buy
119,650
+20,303
+20% +$176K ﹤0.01% 2267
2021
Q3 		$895K Buy
99,347
+1,683
+2% +$16.6K ﹤0.01% 2226
2021
Q2 		$1.17M Sell
97,664
-4,080
-4% -$46.2K ﹤0.01% 2128
2021
Q1 		$1.27M Sell
101,744
-841,896
-89% -$11.3M ﹤0.01% 1967
2020
Q4 		$14.7M Buy
943,640
+186,575
+25% +$2.19M 0.01% 930
2020
Q3 		$7.15M Buy
757,065
+6,520
+0.9% +$70.5K ﹤0.01% 1037
2020
Q2 		$6.72M Sell
750,545
-12,110
-2% -$112K ﹤0.01% 1020
2020
Q1 		$4.86M Sell
762,655
-74,321
-9% -$551K ﹤0.01% 1057
2019
Q4 		$7.01M Sell
836,976
-1,878
-0.2% -$17.3K ﹤0.01% 1071
2019
Q3 		$7.59M Buy
838,854
+39,399
+5% +$442K 0.01% 1053
2019
Q2 		$8.61M Buy
799,455
+100,473
+14% +$1.07M 0.01% 1004
2019
Q1 		$6.67M Hold
698,982
– – ﹤0.01% 1051
2018
Q4 		$8.02M Buy
698,982
+21,582
+3% +$268K 0.01% 931
2018
Q3 		$11.5M Sell
677,400
-43,203
-6% -$657K 0.01% 904
2018
Q2 		$10.2M Buy
720,603
+100,500
+16% +$1.67M 0.01% 942
2018
Q1 		$11.8M Buy
620,103
+582,981
+1,570% +$12.5M 0.01% 893
2017
Q4 		$609K Buy
37,122
+15,624
+73% +$232K ﹤0.01% 1909
2017
Q3 		$322K Hold
21,498
– – ﹤0.01% 2061
2017
Q2 		$189K Buy
21,498
+11,200
+109% +$71.9K ﹤0.01% 2245
2017
Q1 		$53.5K Hold
10,298
– – ﹤0.01% 2341
2016
Q4 		$31K Sell
10,298
-19,100
-65% -$69.5K ﹤0.01% 2335
2016
Q3 		$136K Hold
29,398
– – ﹤0.01% 2533
2016
Q2 		$170K Hold
29,398
– – ﹤0.01% 2492
2016
Q1 		$178K Sell
29,398
-283,267
-91% -$1.7M ﹤0.01% 2462
2015
Q4 		$2.85M Sell
312,665
-248,749
-44% -$1.92M ﹤0.01% 1273
2015
Q3 		$3.17M Buy
561,414
+42,318
+8% +$349K ﹤0.01% 1221
2015
Q2 		$5.76M Sell
519,096
-2,602
-0.5% -$33.5K 0.01% 1024
2015
Q1 		$8.18M Sell
521,698
-3,000
-0.6% -$46.4K 0.01% 928
2014
Q4 		$7.98M Buy
524,698
+274,400
+110% +$3.33M 0.01% 930
2014
Q3 		$2.7M Buy
250,298
+10,000
+4% +$131K ﹤0.01% 1206
2014
Q2 		$3.67M Hold
240,298
– – ﹤0.01% 1115
2014
Q1 		$4.34M Buy
240,298
+19,700
+9% +$380K ﹤0.01% 1075
2013
Q4 		$3.06M Buy
220,598
+1,600
+0.7% +$18.4K ﹤0.01% 1132
2013
Q3 		$2.29M Hold
218,998
– – ﹤0.01% 1200
2013
Q2 		$1.71M Buy
+218,998
New +$1.91M ﹤0.01% 1266

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS AM's SGMO Position: Q3 2023 in Review

UBS AM sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2023, closing a stake of 152,662 shares — an estimated $269K sold.

UBS AM first reported a position in SGMO in Q2 2013 and held it in 41 quarters. The position peaked at $14.7M in Q4 2020. 134 funds tracked by Wall St. Rank hold SGMO as of Q3 2023.

  • UBS AM reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 152,662 SANGAMO THERAPEUTICS INC shares in Q3 2023, an estimated $269K.
  • UBS AM first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 41 quarters.
  • UBS AM's SANGAMO THERAPEUTICS INC position peaked at $14.7M in Q4 2020.
  • 134 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.